Jacobs Levy Equity Management, Inc Idera Pharmaceuticals, Inc. Transaction History

Jacobs Levy Equity Management, Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$1.01 - $1.58 $227,518 - $355,920	-225,266 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.23 - $5.98 $232,214 - $1.13 Million	188,792 Added 517.61%	225,266 $293,000
Q4 2020 Feb 16, 2021	SELL	$2.09 - $5.18 $172,675 - $427,971	-82,620 Reduced 69.37%	36,474 $134,000
Q3 2020 Nov 16, 2020	BUY	$1.71 - $2.68 $24,097 - $37,766	14,092 Added 13.42%	119,094 $255,000
Q2 2020 Aug 17, 2020	BUY	$1.23 - $2.12 $10,237 - $17,644	8,323 Added 8.61%	105,002 $188,000
Q1 2020 May 15, 2020	SELL	$1.06 - $2.15 $64,234 - $130,287	-60,599 Reduced 38.53%	96,679 $128,000
Q4 2019 Feb 14, 2020	BUY	$1.45 - $2.79 $228,053 - $438,805	157,278 New	157,278 $286,000

Ticker IDRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,296,900
Market Cap $188M
Description
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating s...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.